<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 3, 1999
-------------------
Oncor, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Maryland
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-16177 52-1310084
------------------------ ------------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
209 Perry Parkway, Gaithersburg, Maryland 20877
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(301) 963-3500
----------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
N.A.
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
Item 5. Other Events
- ------- ------------
See attached press release.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Oncor, Inc.
-------------------------------------
(Registrant)
By: /s/ Joseph R. Shaya
----------------------------------
Name: Joseph R. Shaya
Title: Acting President and CEO
Dated: September 3, 1999
<PAGE>
ONCOR
Press Release
- --------------------------------------------------------------------------------
For Further Information Contact: Oncor, Inc.
- -------------------------------- 209 Perry Parkway
Joseph R. Shaya Gaithersburg MD 20877
Acting President and CEO (301) 963-3500
Fax (301) 330-3940
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
- ---------------------
ONCOR RECEIVES COURT APPROVAL OF THE SALE OF CERTAIN ASSETS
-----------------------------------------------------------
Gaithersburg, Maryland -- September 2, 1999...Oncor, Inc. announced that it has
received court approval of the sale of certain of its assets. Following a
hearing, the United States Bankruptcy Court for the District of Delaware
authorized Oncor to transfer certain of its licenses and patent rights. In the
first of three separate transactions, Oncor received authorization to transfer
all of its rights to that certain invention known as Rolling Circle
Amplification Technology to RCAT Partners L.L.C. in exchange for payment in the
amount of $700,000. Oncor has also been authorized to transfer all of its
interests in certain technologies known as the "Sunrise (R) Properties" to
Intergen Company for the sum of $525,000. Pursuant to the third transaction
approved by the Court, Oncor has agreed to transfer its interests in seven
license agreements relating to technologies in the field of cancer research to
Virco Ireland, Ltd. for $2.75 million. All three transactions are subject to
typical closing conditions.
As previously reported, on February 26, 1999, Oncor and its wholly-owned
subsidiary, Codon Pharmaceuticals, Inc. filed voluntary petitions for relief
under Chapter 11 of the United States Code in the United States Bankruptcy Court
for the District of Delaware.
# # #
